Blockchain Registration Transaction Record

GeoVax Advances Mpox, COVID Vaccines & Cancer Therapy in Q3 2025

GeoVax reports Q3 2025 progress on Mpox vaccine, multi-antigen COVID-19 vaccine for immunocompromised patients, and expanded cancer therapy programs with strong clinical data and regulatory advancements.

This news matters because GeoVax's advancements address critical gaps in global health security and patient care. Their multi-antigen COVID-19 vaccine shows promise for the over 40 million immunocompromised Americans who don't respond adequately to current vaccines, potentially saving lives in vulnerable populations. The accelerated Mpox vaccine development comes at a crucial time as outbreaks continue globally, addressing constrained vaccine supply and supporting pandemic preparedness. The oncology program expansion into solid tumors represents progress against difficult-to-treat cancers where current treatments often fail. These developments align with national priorities for domestic biomanufacturing and health security, reducing dependency on foreign suppliers while advancing equitable access to life-saving medical innovations.